Portage Biotech (NASDAQ:ALP) Insider Fiorenzo Villani Purchases 4,265 Shares of Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani acquired 4,265 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were bought at an average cost of $4.05 per share, with a total value of $17,273.25. Following the completion of the acquisition, the insider directly owned 38,886 shares of the company’s stock, valued at $157,488.30. The trade was a 12.32% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Fiorenzo Villani also recently made the following trade(s):

• On Tuesday, September 15th, Fiorenzo Villani bought 7,900 shares of Portage Biotech stock. The stock was bought at an average price of $4.15 per share, for a total transaction of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani bought 10,382 shares of Portage Biotech stock. The stock was bought at an average cost of $4.07 per share, with a total value of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani bought 2,000 shares of Portage Biotech stock. The shares were bought at an average price of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani purchased 7,000 shares of Portage Biotech stock. The shares were purchased at an average cost of $5.07 per share, for a total transaction of $35,490.00.

Portage Biotech Stock Performance

ALP stock opened at $4.50 on Friday. The company has a market cap of $6.97 million, a P/E ratio of -0.01 and a beta of 0.54. Portage Biotech Inc. has a 1 year low of $3.20 and a 1 year high of $690.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The stock’s fifty day moving average price is $9.78 and its 200-day moving average price is $14.39.

Portage Biotech (NASDAQ:ALP) last posted its quarterly earnings data on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The firm had revenue of $0.05 million for the quarter. On average, equities analysts forecast that Portage Biotech Inc. will post -14 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALP has been the subject of several research reports. Wall Street Zen raised shares of Portage Biotech to a “hold” rating in a research report on Saturday, September 12th. HC Wainwright assumed coverage on shares of Portage Biotech in a research report on Monday, August 17th. They set a “neutral” rating and a $12.50 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. Finally, Zacks Research upgraded shares of Portage Biotech to a “hold” rating in a research report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Portage Biotech has a consensus rating of “Reduce” and a consensus target price of $12.50.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.